United Therapeutics Corporation (NASDAQ:UTHR) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of United Therapeutics Corporation (NASDAQ:UTHR) have been assigned a consensus recommendation of “Moderate Buy” from the twelve analysts that are covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $533.5455.

A number of analysts have issued reports on the stock. UBS Group reiterated a “buy” rating on shares of United Therapeutics in a research note on Tuesday, February 17th. Royal Bank Of Canada lifted their price objective on shares of United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a report on Thursday. Jefferies Financial Group reiterated a “buy” rating and set a $575.00 target price on shares of United Therapeutics in a report on Wednesday, November 19th. Wells Fargo & Company boosted their price target on shares of United Therapeutics from $423.00 to $466.00 and gave the stock an “equal weight” rating in a research note on Thursday. Finally, HC Wainwright upped their price objective on United Therapeutics from $525.00 to $600.00 and gave the stock a “buy” rating in a research report on Thursday.

United Therapeutics Stock Up 0.1%

UTHR opened at $503.90 on Friday. United Therapeutics has a 52 week low of $266.98 and a 52 week high of $537.19. The business has a fifty day simple moving average of $484.38 and a 200-day simple moving average of $445.92. The firm has a market cap of $22.09 billion, a P/E ratio of 18.06, a P/E/G ratio of 1.79 and a beta of 0.85.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. During the same quarter in the previous year, the business earned $6.19 EPS. The company’s quarterly revenue was up 7.4% compared to the same quarter last year. Sell-side analysts expect that United Therapeutics will post 24.48 earnings per share for the current year.

Insiders Place Their Bets

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $476.34, for a total value of $3,953,622.00. Following the sale, the executive vice president owned 36,781 shares of the company’s stock, valued at $17,520,261.54. This trade represents a 18.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Michael Benkowitz sold 14,440 shares of the business’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $472.13, for a total value of $6,817,557.20. The SEC filing for this sale provides additional information. Insiders have sold a total of 407,954 shares of company stock worth $197,601,528 in the last quarter. 10.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On United Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mishpacha Holdings Corp acquired a new stake in United Therapeutics during the fourth quarter worth approximately $487,000. Seven Fleet Capital Management LP acquired a new position in shares of United Therapeutics in the 4th quarter valued at $633,000. DGS Capital Management LLC grew its position in shares of United Therapeutics by 20.3% in the 4th quarter. DGS Capital Management LLC now owns 841 shares of the biotechnology company’s stock valued at $410,000 after buying an additional 142 shares during the last quarter. Kera Capital Partners Inc. acquired a new stake in United Therapeutics during the 4th quarter worth $208,000. Finally, Dorsey Wright & Associates acquired a new stake in United Therapeutics during the 4th quarter worth $2,499,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Q4 outperformance and growth target — UTHR beat EPS expectations (reported strength in Tyvaso DPI sales) and management is targeting roughly a $4B revenue run‑rate by 2027 as several late‑stage product launches approach; this underpins the recent rally and longer‑term growth thesis. Read More.
• Positive Sentiment: Analysts lifting targets — Multiple firms raised price targets (examples: H.C. Wainwright, RBC, Oppenheimer), which supports further upside and institutional interest. Read More.
• Positive Sentiment: Bullish options flow — Unusually large call buying around the print suggests traders are positioning for further upside or volatility in the short term. Read More.
• Neutral Sentiment: Technical/relative strength recognition — UTHR earned a high RS rating (91), signaling market leadership but not guaranteeing direction near term. Read More.
• Neutral Sentiment: Mixed analyst views remain — while many bumped targets, some firms kept Hold/equal‑weight ratings, leaving near‑term consensus mixed. Read More.
• Negative Sentiment: Revenue missed consensus — Q4 revenue came in below Street estimates, which sparked an earlier pullback and is a reminder top‑line execution matters for the multiple. Read More.
• Negative Sentiment: Insider selling — The COO and a director disclosed multi‑lot sales in February (COO sale worth several million and director sales disclosed), which can create investor concern about near‑term insider conviction. Read More. Read More.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.